Protective effects of matrine on experimental autoimmune encephalomyelitis via regulation of ProNGF and NGF signaling

Experimental and Molecular Pathology

Volumn 100, Issue 2, 2016, Pages 337-343

  Zhu, Lin ^a   Pan, Qing xia ^a   Zhang, Xiao Jian ^a   Xu, Yu Ming ^a   Chu, Yao juan ^a   Liu, Nan ^a   Lv, Peng ^a   Zhang, Guang Xian ^b   Kan, Quan Cheng ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

MS EAE; NGF; Oligodendrocytes; P75NTR; ProNGF; TrkA

Indexed keywords

MATRINE; NERVE GROWTH FACTOR RECEPTOR; NEUROTROPHIN RECEPTOR P75; PROTEIN TYROSINE KINASE A; ALKALOID; NERVE GROWTH FACTOR; NEUROPROTECTIVE AGENT; PRO-NERVE GROWTH FACTOR, RAT; PROTEIN PRECURSOR; QUINOLIZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BODY WEIGHT; CELL DEATH; CELL DIFFERENTIATION; CELL SURVIVAL; CONTROLLED STUDY; DEMYELINATING DISEASE; DISEASE SEVERITY; DRUG EFFICACY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; IMMUNOHISTOCHEMISTRY; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; OLIGODENDROGLIA; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; ANIMAL; AXON; CENTRAL NERVOUS SYSTEM; CHEMISTRY; DEMYELINATING DISEASES; DRUG EFFECTS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; PATHOLOGY; PHYTOTHERAPY; PROCEDURES; SOPHORA; WISTAR RAT;

ALKALOIDS; ANIMALS; APOPTOSIS; AXONS; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM; DEMYELINATING DISEASES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOHISTOCHEMISTRY; NERVE GROWTH FACTORS; NEUROPROTECTIVE AGENTS; OLIGODENDROGLIA; PHYTOTHERAPY; PROTEIN PRECURSORS; QUINOLIZINES; RATS, WISTAR; SIGNAL TRANSDUCTION; SOPHORA;

EID: 84960347543     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2015.12.006     Document Type: Article

References (41)

1. Acosta C.M., Cortes C., MacPhee H., et al. Exploring the role of nerve growth factor in multiple sclerosis: implications in myelin repair. CNS Neurol. Disord. Drug Targets 2013, 12(8):1242-1256.
2. Beattie M.S., Harrington A.W., Lee R., et al. ProNGF induces p75-mediated death of oligodendrocytes following spinal cord injury. Neuron 2002, 36(3):375-386.
3. Bradshaw R.A., Pundavela J., Biarc J., et al. NGF and ProNGF: regulation of neuronal and neoplastic responses through receptor signaling. Adv. Biol. Regul. 2015, 58:16-27. 10.1016/j.jbior.2014.11.003.
4. Brück W., PfÖrtner R., Pham T., et al. Reduced astrocytic NF-B activation by laquinimod protects from cuprizone-induced demyelination. Acta Neuropathol. 2012, 124(3):411-424. 10.1007/s00401-012-1009-1.
5. Chang A., Nishiyama A., Peterson J., et al. NG2-positive oligodendrocyte progenitor cells in adult human brain and multiple sclerosis lesions. J. Neurosci. 2000, 20(17):6404-6412.
6. Cudrici C., Niculescu T., Niculescu F., et al. Oligodendrocyte cell death in pathogenesis of multiple sclerosis: protection of oligodendrocytes from apoptosis by complement. J. Rehabil. Res. Dev. 2006, 43(1):123-132.
7. Fahnestock M., Yu G., Michalski B., et al. The nerve growth factor precursor proNGF exhibits neurotrophic activity but is less active than mature nerve growth factor. J. Neurochem. 2004, 89(3):581-592. 10.1111/j.1471-4159.2004.02360.x.
8. Fortress A.M., Buhusi M., Helke K.L., et al. Cholinergic degeneration and alterations in the TrkA and p75NTR balance as a result of pro-NGF injection into aged rats. J. Aging Res. 2011, 2011:460543. 10.4061/2011/460543.
9. Fukushima S., Nishikawa K., Furube E., et al. Oligodendrgenesis in the fornix of adult mouse brain: the effect of LPS-induced inflammatory stimulation. Brain Res. 2015, 1627:52-69. 10.1016/j.brainres.2015.09.011.
10. Gu C., Casaccia-Bonnefil P., Srinivasan A., et al. Oligodendrocyte apoptosis mediated by caspase activation. J. Neurosci. 1999, 9(8):3043-3049.
11. Hartung H.P., Aktas O., Menge T., et al. Immune regulation of multiple sclerosis. Handb. Clin. Neurol. 2014, 122:3-14. 10.1016/B978-0-444-52001-2.00001-7.
12. Hayashi K., Storesund T., Schreurs O., et al. Nerve growth factor beta/pro-nerve growth factor and their receptors in normal human oral mucosa. Eur. J. Oral Sci. 2007, 115(5):344-354.
13. Kan Q.C., Pan Q.X., Zhang X.J., et al. Matrine ameliorates experimental autoimmune encephalomyelitis by modulating chemokines and their receptors. Exp. Mol. Pathol. 2015, 99(2):212-219. 10.1016/j.yexmp. 2015.06.008.
14. Kerschensteiner M., Stadelmann C., Dechant G., et al. Neurotrophic cross-talk between the nervous and immune systems: implications for neurological diseases. Ann. Neurol. 2003, 53(3):292-304. 10.1002/ana.10446.
15. Kim H.N., Kim Y.R., Ahn S.M., et al. Protease activated receptor-1 antagonist ameliorates the clinical symptoms of experimental autoimmune encephalomyelitis via inhibiting breakdown of blood-brain barrier. J. Neurochem. 2015, 135(3):577-588. Epub 2015 Sep 22. 10.1111/jnc.13285.
16. Lee D.H., Steinacker P., Seubert S., et al. Role of glial 14-3-3 gamma protein in autoimmune demyelnation. J. Neuroinflammation 2015, 12:187. 10.1186/s12974-015-0381-x.
17. Lee J.Y., Kang S.R., Yune T.Y. Fluoxetine prevents oligodendrocyte cell death by inhibiting microglia activation after spinal cord injury. J. Neurotrauma 2015, 32(9):633-644. 10.1089/neu.2014.3527.
18. Liu N., Kan Q.C., Zhang X.J., et al. Upregulation of immunomodulatory molecules by matrine treatment in experimental autoimmune encephalomyelitis. Exp. Mol. Pathol. 2014, 97(3):470-476. 10.1016/j.yexmp.2014.10.004.
19. Long Y., Lin X.T., Zeng K.L., et al. Efficacy of intramuscular matrine in the treatment of chronic hepatitis B. Hepatobiliary Pancreat. Dis. Int. 2004, 3(1):69-72.
20. Massella A., D'Intino G., Fernández M., et al. Gender effect on neurodegeneration and myelin markers in an animal model for multiple sclerosis. BMC Neurosci. 2012, 10.1186/1471-2202-13-12.
21. Micera A., Properzi F., Triaca V., et al. Nerve growth factor antibody exacerbates neuropathological signs of experimental allergic encephalomyelitis in adult Lewis rats. J. Neuroimmunol. 2000, 104(2):116-123.
22. Miron V.E., Kuhlmann T., Antel J.P. Cells of the oligodendroglial lineage, myelination, and remyelination. Biochim. Biophys. Acta 2011, 1812(2):184-193. 10.1016/j.bbadis.2010.09.010.
23. Mukai J., Suvant P., Sato T.A. Nerve growth factor-dependent regulation of NADE-induced apoptosis. Vitam. Horm. 2003, 66:385-402.
24. Naesse E.P., Schreurs O., Messelt E., et al. Distribution of nerve growth factor, pro-nerve growth factor, and their receptors in human salivary glands. Eur. J. Oral Sci. 2013, 121(1):13-20. 10.1111/eos.12008.
25. Niederhauser O., Mangold M., Schubenel R., et al. NGF ligand alters NGF signaling Via p75NTR and TrkA. J. Neurosci. Res. 2000, 61(3):263-272.
26. Ogawa S., Tokumoto Y., Miyake J., et al. Immunopanning selection of A2B5-positive cells increased the differentiation efficiency of induced pluripotent stem cells into oligodendrocyes. Neurosci. Lett. 2011, 489(2):79-83. 10.1016/j.neulet.2010.11.070.
27. Paoletti F., Malerba F., Ercole B.B., et al. A comparative analysis of the structural, functional and biological differences between mouse and human nerve growth factor. Biochim. Biophys. Acta 2015, 1854(3):187-197. 10.1016/j.bbapap.2014.12.005.
28. Penkowa M., Hidalgo J. Treatment with metallothionein prevents demyelination and axonal damage and increases oligodendrocyte precursors and tissue repair during experimental autoimmune encephalomyelitis. J. Neurosci. Res. 2003, 72(5):574-586.
29. Skundric D.S., Cruikshank W.W., Montgomery P.C., et al. Emerging role of IL-16 in cytokine-mediated regulation of multiple sclerosis. Cytokine 2015, 75(2):234-248. 10.1016/j.cyto.2015.01.005.
30. Triaca V., Tirassa P., Aloe L., et al. Presence of nerve growth factor and TrkA expression in the SVZ of EAE rats: evidence for a possible functional significance. Exp. Neurol. 2005, 191(1):53-64. 10.1016/j.expneurol.2004.08.034.
31. Wang T., Liu Y.Y., Wang X., et al. Protective effects of octacosanol on 6-hydroxydopamine-induced parkinsonism in rats via regulation of ProNGF and NGF signaling. Acta Pharmacol. Sin. 2010, 31(7):765-774. 10.1038/aps.2010.69.
32. Wüst S., van den Brandt J., Reichardt H.M., et al. Preventive treatment with methylprednisolone paradoxically exacerbates experimental autoimmune encephalomyelitis. Int. J. Endocrinol. 2012, 2012:417017. 10.1155/2012/417017.
33. Yin L.L., Lin L.L., Zhang L., et al. Epimedium flavonoids ameliorate experimental autoimmune encephalomyelitis in rats by modulating neuroinflammatory and neurotrophic responses. Neuropharmacology 2012, 63(5):851-862. 10.1016/j.neuropharm.2012.06.025.
34. Yune T.Y., Lee J.Y., Jung G.Y., et al. Minocycline alleviates death of oligodendrocytes by inhibiting pro-nerve growth factor production in microglia after spinal cord injury. J. Neurosci. 2007, 27(29):7751-7761. 10.1523/JNEUROSCI.1661-07.2007.
35. Zeldich E., Chen C.D., Avila R., et al. The anti-aging protein kiotho enhances remyelination following cuprizone-induced demyelination. J. Mol. Neurosci. 2015, 57(2):185-196. 10.1007/s12031-015-0598-2.
36. Zelena D., Makara B.G. Steroids: the physiological and pharmacological effects of glucocorticoids. Orv. Hetil. 2015, 156(35):1415-1425. 10.1556/650.2015.30248.
37. Zhang J., Li Y., Lu M., et al. Bone marrow stromal cells reduce axonal loss in experimental autoimmune encephalomyelitis mice. J. Neurosci. Res. 2006, 84(3):587-595. 10.1002/jnr.20962.
38. Zhang L., Wang T., Wen X., et al. Effect of matrine on HeLa cell adhesion and migration. Eur. J. Pharmacol. 2007, 563(1-3):69-76.
39. Zhang J., Li Y., Zheng X., et al. Bone marrow stromal cells protect oligodendrocytes from oxygen-glucose deprivation injury. J. Neurosci. Res. 2008, 86(7):1501-1510. 10.1002/jnr.21617.
40. Zhang J., Brodie C., Li Y., et al. Bone marrow stromal cell therapy reduces proNGF and p75 expression in mice with experimental autoimmune encephalomyelitis. J. Neurol. Sci. 2009, 279(1-2):30-38. 10.1016/j.jns.2008.12.033.
41. Zhang S., Kan Q.C., Xu Y., et al. Inhibitory effect of matrine on blood-brain barrier disruption for the treatment of experimental autoimmune encephalomyelitis. Mediat. Inflamm. 2013, 2013:736085. 10.1155/2013/736085.